This curriculum vitae summarizes the qualifications and experience of Muhammad R Malik. He has a Ph.D. in microbiology and over 14 years of laboratory research experience focusing on pathogenic bacteria, tuberculosis, and antibiotic drug development. He has managed microbiology laboratories, published around 40 papers, and has teaching experience. His professional positions include senior research roles studying antibiotic mechanisms and resistance.

1. CURRICULUM VITAE
Muhammad R Malik
1402 Yosko Dr, Edison, NJ 08817
Ph: 732-766-4695
E-mail: malikhafsa58@gmail.com
OVERVIEW
• Ph.D. in microbiology
• 14 years laboratory research in microbiology/pathogenic bacteria/TB/drug
development (antibiotics)
• 10+ years laboratory management experience
• Working experience in BSL-2 and BSL3 facilities
• Almost 40 publications
• Teaching, oral communication experience
• Written and interpersonal communication: scientific publications, scientific
collaborations
• Proficient in Microsoft office (Word, Excel, PowerPoint, etc.)
EDUCATION
1988-91: New York University, School of Medicine, MS (Microbiology)
1991-95: New York University, School of Medicine, PhD (Microbiology)
1999-00: Senior Postdoctoral Fellow, Laboratoire d’Analyse, Department of Biology,
University of Lausanne, Switzerland (DNA structure research)
PROFESSIONAL POSITIONS
Feb 2001-Aug 2015: Senior Research Associate, Public Health Research Institute, New
Jersey Medical School, Rutgers University, Newark, NJ (antibiotic research)
August 2000- January 2001: Assistant Professor (Microbiology) Faculty of Medicine,
International Islamic University, Kuantan, Malaysia (teaching medical students,
research)
July1995-June 1999: Senior Microbiologist, NIH Islamabad, Pakistan
SPECIALIZED EXPERIENCE
Management experience
- Routinely train and supervise students, both in laboratory and communication
skills
- Supervise Microbiology testing, report review, quality and safety
- Implement safety procedures
- Assist PI in hiring, training, and performance appraisal
- Implement safety procedures
- Implement procedures for storing, dispensing, and disposing of supplies and
equipment
- Manage inventory and resources
- Coordinate maintenance of equipment and space
1

2. - Coordinate receipt and delivery of supplies and equipment
- Ensure compliance with applicable regulations
- Resolve issues
- Organize lab meetings
Research experience
- Team leader on a study to develop novel fluoroquinolones as potential anti-
tuberculosis agents
- Vast experience in monitoring antibacterial activities of compounds against a
variety of bacterial species
- Mechanism of action of fluoroquinolones (a class of antibiotics); fluoroquinolone
resistance
- Design and perform microbiology experiments efficiently and independently
- Culture and handling infectious bacteria (Mycobacterium tuberculosis)
- Microbiology tests (MIC, LD, MBC, MPC)
- Experience in conducting minimal inhibitory concentration (MIC) experiments
using broth microdilution techniques, as well as time-kill studies
- Assess combinations of antibacterial agents for synergy both with time-kill and
checkerboard types of assays
- Experience in measuring the frequency of resistance of compounds using a large
inoculum approach
- 5 years experience in a regulated biopharmaceutical environment
- Molecular biology techniques (PCR, cloning, gel electrophoresis, ultracentrifugation,
radioactive isotopes, genetic manipulations of bacteria)
- Oral communication (seminars and group discussions)
- Written communication (research publications, standard operating procedures,
laboratory reports)
- Proficient in Microsoft office (Word, Excel, PowerPoint, etc.)
Industrial experience
- Production and quality control of biopharmaceuticals (vaccines for measles,
polio, and rabies).
- Supervised production ranging from basic, in-process to final container
- Performed and supervised microbiology, cell culture, and animal tests. These
tests include sterility, environment monitoring, potency, identity, safety,
mycoplasma, presence of adventitious agents, etc.
- Performed quality assurance, documentation, writing standard operating
procedures, and product release etc.
Laboratory qualifications, trainings
- Laboratory Safety
- Biosafety/Blood borne Pathogens Refresher
- Biosafety level-3 laboratory: Bacterial Agents, M. tuberculosis
- Viral Agents
- Select Agent
- Respirator-PAPR
- Respiratory Protection
- FBI Insider Threat
- IATA training for handling and shipping biohazard materials
- Radioactivity safety
2

3. PUBLICATIONS
1. Drlica, K., Malik, M., and Rouviere-Yaniv, J. 1992. Intracellular DNA
supercoiling in bacteria. Nucleic Acids & Molecular Biology 6: 55-66.
2. Drlica, K., Malik, M., Wang, J.-Y., Sasiak, A., and Sinden, R. 1994. Analysis of
DNA supercoiling. Methods in Gene Technology 2: 253-280.
3. Malik, M. 1995. Genetic interactions between DNA gyrase and histone-like
protein, HU. Ph.D. Thesis, New York University. 145 pp.
4. Friedman, S. M., Malik, M., and Drlica, K. 1995. DNA supercoiling in a
thermotolerant mutant of Escherichia coli. Mol. Gen. Genet. 248: 417-422.
5. Drlica, K., Malik, M., Wang, J.-Y, Levitz, R., and R. Burger. 1995. The
fluoroquinolones as antituberculosis agents. In Tuberculosis. W. Rom and S.
Garay, Eds. Little, Brown and Co, NY. pp. 817-827.
6. Malik, M., Bensaid, A., Rouviere-Yaniv, J., and Drlica, K. 1996. Histone-like
protein HU and bacterial DNA topology: suppression of an HU deficiency by
gyrase mutations. J. Mol. Biol. 256:66-76.
7. Chen, C.-R., Malik, M., Snyder, M., and Drlica, K. 1996. DNA gyrase and
topoisomerase IV on the bacterial chromosome: quinolone-induced DNA
cleavage. J. Mol. Biol. 258:627-637.
8. Drlica, K., Xu, J.-Y. Wang, Burger, R., and Malik, M. 1996. Fluoroquinolone
action in mycobacteria: similarity with effects in Escherichia coli and detection
by cell lysate viscosity. Antimicrob. Agents Chemother. 40: 1594-1599.
9. Drlica, K., Wu, E.-D., Chen, C.-R., Wang, J.-Y., Zhao, X., Xu, C., Qiu, L., and
Malik, M. 1999. Prokaryotic DNA topology. In Prokaryotic Gene Expression
(Frontiers in Molecular Biology). S. Baumberg, Ed. Oxford. pp. 141-168.
10. Lu, T., Malik, M., and Drlica-Wagner, A. 2001. C-8-methoxy fluoroquinolones.
Research Advances in Antimicrob. Agents Chemother. 2: 29-42.
11. Drlica, K., and Malik. M. 2003. Fluoroquinolones: action and resistance. Curr.
Top. Med. Chem. 3: 249-282.
12. Drlica, K., Lu, T., Malik, M., and Zhao, X. 2004. Fluoroquinolones as
antituberculosis agents. In Tuberculosis, W. Rom and S. Garay, Eds.
Lippincott Williams & Wilkins. pp. 791-807.
13. Malik, M., Lu, T., Zhao, X., Singh, A., Hatten, C., Domagala, J., Kerns, R., and
Drlica, K. 2005. Lethality of quinolones against Mycobacterium smegmatis in
the presence or absence of chloramphenicol. Antimicrob. Agents Chemother.
49: 2008-2014. doi:10.1128/AAC.49.5.2008–2014.2005
14.Zhao, X., Malik, M., Chan, N., Drlica-Wagner, A., Wang, J.-Y., Li, X., and Drlica,
K. 2006. Lethal action of quinolones against a temperature-sensitive dnaB
replication mutant of Escherichia coli. Antimicrob. Agents Chemother. 50: 362-
364. doi:10.1128/AAC.50.1.362–364.2006
15. Malik, M., and Drlica, K. 2006. Moxifloxacin lethality against Mycobacterium
tuberculosis in the presence and absence of chloramphenicol. Antimicrob.
Agents Chemother. 50: 2842-2844. doi:10.1128/AAC.00250-06
16. Malik, M., Zhao, X., and Drlica, K. 2006. Lethal fragmentation of bacterial
chromosomes mediated by DNA gyrase and quinolones. Mol. Microbiol. 61:
810-825. doi:10.1111/j.1365-2958.2006.05275.x
3

4. 17. Quinn, B., Hussain, S. Malik, M., Drlica, K. and Zhao, X. 2007. Daptomycin
inoculum effects and mutant prevention concentration with Staphylococcus
aureus. J. Antimicrob. Agents Chemother. 60: 1380-1383.
doi:10.1093/jac/dkm375
18. Malik, M., Hussain, S., and Drlica, K. 2007. Effect of anaerobic growth on
quinolone lethality with Escherichia coli. Antimicrob. Agents Chemother. 51: 28-
34. doi:10.1128/AAC.00739-06
19. 19. Drlica, K., Malik, M., Kerns, R., and Zhao, X. 2008. Quinolone-mediated
bacterial death. Antimicrob. Agents Chemother. 52: 385-392.
doi:10.1128/AAC.01617-06
20. *German, N., *Malik, M., Drlica, K., and Kerns, R. 2008. Use of gyrase
resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.
Antimicrob. Agents Chemother. 52: 3815-3921. doi: 10.1128/AAC.00330-08.
21. Drlica, K., Wang, J.-Y., Malik, M., Lu, T., Park, S., Li, X., Perlin, D., and Zhao,
X. 2008. An anti-mutant approach for antimicrobial use. In Antimicrobial
Resistance and Implications for the 21st
Century, I.W. Fong and K. Drlica, Eds.
Springer, New York., pp.371-400.
22. Hussain, S., Malik, M., Shi, L., Gennaro, M., and Drlica, K. 2009. In vitro model
of mycobacterial growth arrest using nitric oxide with limited air. Antimicrob.
Agents Chemother. 53:157-161. doi: 10.1128/AAC.00442-08.
23. Drlica, K., Zhao, X., and Malik, M. 2009. Pathogenesis: Quinolones. In
Encyclopedia of Microbiology, M. Schaechter, Ed. Elsvier, Oxford. pp. 707-716.
24.Malik, M., Capecci, J., and Drlica, K. 2009. Lon protease is essential for
paradoxical survival of Escherichia coli exposed to high concentrations of
quinolone. Antimicrob. Agents Chemother. 53: 3103-3105. doi:
10.1128/AAC.00019-09.
25. Drlica, K., Hiasa, H., Kerns, R., Malik, M., Mustaev, A., and Zhao, X. 2009.
Quinolones: action and resistance updated. Curr. Top. Med. Chem. 9:981-998.
26.Malik M, Hoatam G, Chavda K, Kerns RJ, Drlica K. 2010. Novel approach for
comparing the abilities of quinolones to restrict the emergence of resistant
mutants during quinolone exposure. Antimicrob. Agents Chemother. 54: 149-
156. doi: 10.1128/AAC.01035-09.
27. Wang, X., Zhao, X., Malik, M., and Drlica, K. 2010. Contribution of reactive
oxygen species to pathways of quinolone-mediated bacterial cell death. J.
Antimicrob. Chemother. 65:520-524. doi: 10.1093/jac/dkp486.
28. Han, X., Dorsey-Oresto, A., Malik, M., Wang, J.-Y., Drlica, K., Zhao, Z., and Lu,
T. 2010. Escherichia coli genes that reduce the lethal effects of stress. BMC
Microbiol. Feb 4;10:35. doi: 10.1186/1471-2180-10-35.
29. Malik, M., Marks, K. R., Schwanz, H., German, N., Drlica, K., and Kerns R. J.
2010. Effect of N-1/C-8 ring fusion and C-7 ring structure on fluoroquinolone
lethality. Antimicrob. Agents Chemother. 54;5214-5221. doi:
10.1128/AAC.01054-10.
4

5. 30. Malik, M., Marks, K. R., Mustaev, A., Zhao, X., Chavda, K., Kerns, R. J., and
Drlica, K. 2011. Fluoroquinolone and quinazolinedione activities against wild-
type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob.
Agents Chemother. 55:2335-2343. doi: 10.1128/AAC.00033-11.
31. Marks, K. R., Malik, M., Mustaev, A., Hiasa, H., Drlica, K., and Kerns, R. J.
2011. Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy
fluoroquinolones. Bioorganic & Medicinal Chemistry Letters. 21;4585-4588. doi:
10.1016/j.bmcl.2011.05.112.
32. Drlica, K., Zhao, X., Malik, M., Salz, T., and Kerns, R. 2012 Fluoroquinolone
resistance: mechanisms, restrictive dosing, and anti-mutant screening
strategies for new compounds. In Antibiotic Discovery and Development. M. J.
Pucci and T. J. Dougherty, Eds. Springer-Verlag. pp. 485-514.
33. Malik, M., Chavda, K., Zhao, X., Shah, N., Hussain, S., Kurepina, N.,
Kreisworth, B., Kerns, R., and Drlica. K. 2012. Induction of mycobacterial
resistance to quinolone-class antimicrobials. Antimicrob. Agents Chemother.
56:3879-3887. doi: 10.1128/AAC.00474-12
34. Hussain S, Malik F, Hameed A, Ahmed S, Riaz H, Abbasi N, Malik M. 2012.
Pakistani pharmacy students’ perception about complementary and alternative
medicine. Am J Pharm Educ. 2012;76(2):21. doi: 10.5688/ajpe76221
35. Mustaev, A., Malik, M., Zhao, X., Kurepina, N., Luan, G., Oppegard, L.M.,
Hiasa, H., Marks, K. R., Kerns, R. J., Berger J.M., and Drlica, K. 2014.
Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding. J. Biol.
Chem. 289:12300-12312. doi: 10.1074/jbc.M113.529164.
36. Malik, M., Li, L., Zhao, X., Kerns, R.J., Berger, J. M., and Drlica, K., 2014.
Lethal synergy involving bicyclomycin: an approach for reviving old antibiotics.
J. Antimicrob. Chemother. 69(12):3227-3235. doi: 10.1093/jac/dku285.
37. Li, L., Hong,Y., Mosel, M., Malik, M., Drlica, K., and Zhao, X. 2014. Ribosomal
Elongation Factor 4 Promotes Cell Death Associated with Lethal Stress. mBio
5(6):e01708-14. doi:10.1128/mBio.01708-14.
38. Zhao, X., Malik, M., Hong, Y., Li, L., and Drlica, K. Quinolones. 2014. In
Encyclopedia of Microbiology, Reference Module in Biomedical Sciences,
Michael J. Caplan, Ed. Elsevier. doi:10.1016/B978-0-12-801238-3.02418-1
39. Drlica, K., Zhao, X., Malik, M, Hiasa, H, Mustaev, A, and Kerns R.J.
Fluoroquinolone Resistance. In Bacterial resistance to antibiotics: from
molecules to man. B. Bonev, Ed. Publisher. (in press)
40. Malik, M., Mustaev, Rosen, J.D., Luan, G., Schwanz, H., Shah, N., Oppegard,
L.M., Hiasa, H., Zhao, X., Kerns, R.J., and Drlica, K. 2016. Suppression of
gyrase-mediated resistance by C7 aryl fluoroquinolones. Nucl. Acids Res; 44:
3304–3316. doi: 10.1093/nar/gkw161.
PATENTS
1. Zhao, X, Drlica, K, Malik, M, and Berger J. Antimicrobial synthetic lethality involving
Bicyclomycin. Provisional Application Number: 618055228. Treating a gram-
negative bacterial (Escherichia coli) infection comprises administering bicyclomycin
and agent that inhibits bacterial RNA transcription or the translation of bacterial
5

6. mRNA to a peptide, to a subject. Patent Number: WO2014160814-A1. Patent
Assignee: Rutgers state University, New Jersey; University of California.
INVITED LECTURES
Tetraphase Pharmaceutical, Boston, MA
AstraZeneca, Boston, MA
Bristol-Myers and Squib, New Haven, CT
Public Health Research Institute, New York, NY
Public Health Foundation, New York, NY
HTAA Hospital, Kuantan, Malaysia
Department of Microbiology, University of Karachi
Department of Microbiology, Shah Latif University, Sind
Department of Biology, Quid-i-Azam University, Islamabad
Department of Pathology, Liaqat National Hospital, Karachi
Armed Forces Institute of Pathology, Rawalpindi
Pakistan Council of Science and Industrial Reseat, Lahore
Children Hospital, Pakistan Institute of Medical Sciences, Islamabad
Tuberculosis Hospital, Rawalpindi
Pakistan Science Foundation, Islamabad
Animal Research Institute, National Agriculture Research Council, Islamabad
Department of Biology, Arid Agriculture University, Rawalpindi
STUDENTS TRAINED
Gan Luan (Ph.D. 2015)
Michael Mosel (Ph.D. 2014)
Anubha Singh, (Ph.D. 2004)
Tasneem Shahid (M.Phil. 1996)
Tasneem Shaikh (M.Phil. 1998)
Rahim Shah (M.Phil. 1999)
Nymph Chan (MS 2003)
Alexandra Ward (MS 2005)
Brian Quinn (MS 2005)
Joe Capecci (MS 2008)
Lucy Pao (MS 2008-2009)
Gerard Hoatam (MS 2010)
Kalayan Chavda (MS 2010)
Nirali Shah (MS 2011)
Ali Manzar (MS 2011)
Brian Wey (MS 2014)
Syed Hussain (Tech 2008-2010)
6

7. mRNA to a peptide, to a subject. Patent Number: WO2014160814-A1. Patent
Assignee: Rutgers state University, New Jersey; University of California.
INVITED LECTURES
Tetraphase Pharmaceutical, Boston, MA
AstraZeneca, Boston, MA
Bristol-Myers and Squib, New Haven, CT
Public Health Research Institute, New York, NY
Public Health Foundation, New York, NY
HTAA Hospital, Kuantan, Malaysia
Department of Microbiology, University of Karachi
Department of Microbiology, Shah Latif University, Sind
Department of Biology, Quid-i-Azam University, Islamabad
Department of Pathology, Liaqat National Hospital, Karachi
Armed Forces Institute of Pathology, Rawalpindi
Pakistan Council of Science and Industrial Reseat, Lahore
Children Hospital, Pakistan Institute of Medical Sciences, Islamabad
Tuberculosis Hospital, Rawalpindi
Pakistan Science Foundation, Islamabad
Animal Research Institute, National Agriculture Research Council, Islamabad
Department of Biology, Arid Agriculture University, Rawalpindi
STUDENTS TRAINED
Gan Luan (Ph.D. 2015)
Michael Mosel (Ph.D. 2014)
Anubha Singh, (Ph.D. 2004)
Tasneem Shahid (M.Phil. 1996)
Tasneem Shaikh (M.Phil. 1998)
Rahim Shah (M.Phil. 1999)
Nymph Chan (MS 2003)
Alexandra Ward (MS 2005)
Brian Quinn (MS 2005)
Joe Capecci (MS 2008)
Lucy Pao (MS 2008-2009)
Gerard Hoatam (MS 2010)
Kalayan Chavda (MS 2010)
Nirali Shah (MS 2011)
Ali Manzar (MS 2011)
Brian Wey (MS 2014)
Syed Hussain (Tech 2008-2010)
6